Microbot Medical filings document formal disclosures tied to the LIBERTY Endovascular Robotic System and the company’s commercial-stage medical-device operations. Recent Form 8-K reports furnish Regulation FD press releases on U.S. market release activity, healthcare-system adoption, procedure use, medical-society occupational-protection guidelines, and publication of the ACCESS-PVI pivotal study.
The filings also record Item 8.01 other-event disclosures and capital-markets matters, including an at-the-market common stock program under a shelf registration statement. These records describe the company’s Nasdaq-listed common stock, product commercialization, clinical-evidence communications, commercial organization updates, and related exhibit filings.
Microbot Medical Inc. reported changes to its executive employment arrangements and a one-time cash award. As of February 20, 2026, the company entered into an addendum to the employment agreement with Simon Sharon, an addendum with Rachel Vaknin, and an amendment to the employment agreement with Juan Diaz-Cartelle. On February 18, 2026, the board also authorized a special bonus of approximately $140,000 for CEO, President and Chairman Harel Gadot, which is in addition to bonuses he may receive under his existing employment agreement.
Microbot Medical reported that Tampa General Hospital has become the first health system in Florida to adopt its LIBERTY® Endovascular Robotic System, following recent FDA 510(k) clearance. The company sees this as early post-clearance momentum in a U.S. peripheral endovascular market of about 2.5 million procedures annually.
Microbot began a limited market release of LIBERTY in late 2025 and plans a full commercial launch at the Society of Interventional Radiology conference in April 2026. LIBERTY is described as a single-use, remotely operated robotic system designed to improve precision and reduce radiation exposure and physical strain during peripheral endovascular procedures.
Gadot Harel reported acquisition or exercise transactions in this Form 4 filing.
Microbot Medical Inc. reported that Chairman, President and CEO Harel Gadot received a grant of stock options covering 480,000 shares of common stock. These options were awarded under the company’s 2020 Omnibus Performance Award Plan.
According to the grant terms, 25% of the option vests and becomes exercisable on August 18, 2026. The remaining 75% vests and becomes exercisable in equal installments on a quarterly basis over the following 30 months, subject to the plan’s provisions on possible acceleration or forfeiture.
Diaz-Cartelle Juan reported acquisition or exercise transactions in this Form 4 filing.
Microbot Medical Inc. reported that Chief Medical Officer Juan Diaz-Cartelle received a grant of stock options covering 105,000 shares of common stock. These options were awarded at no cost as part of his compensation.
Under the company’s 2020 Omnibus Performance Award Plan, 25% of the options will vest and become exercisable on August 18, 2026. The remaining 75% will vest in equal installments on a quarterly basis over the following 30 months, subject to possible acceleration or forfeiture under the plan terms.
Sharon Simon reported acquisition or exercise transactions in this Form 4 filing.
Microbot Medical Inc. reported that General Manager and CTO Sharon Simon was granted stock options covering 105,000 shares of common stock. According to the company’s 2020 Omnibus Performance Award Plan, 25% of the options vest and become exercisable on August 18, 2026, with the remaining 75% vesting in equal quarterly installments over the following 30 months, subject to the plan’s acceleration or forfeiture provisions.
Vaknin Rachel reported acquisition or exercise transactions in this Form 4 filing.
Microbot Medical Inc. reported that its Chief Financial Officer, Rachel Vaknin, received a grant of stock options covering 105,000 shares of common stock. The award is a right to buy shares under the company’s 2020 Omnibus Performance Award Plan, as amended.
According to the grant terms, 25% of the options will vest and become exercisable on August 18, 2026. The remaining 75% will vest and become exercisable in equal installments on a quarterly basis over the following 30 months, subject to possible acceleration or forfeiture under the plan.
Microbot Medical Inc. filed an 8-K to share that CEO, President and Chairman Harel Gadot will be a featured panelist at The Surgical Disruptive Technology Summit during the SAGES NBT Innovation Weekend in Houston. He will join a session on endovascular therapeutics, AI and robotics.
The company uses this event to spotlight its LIBERTY Endovascular Robotic System, described as the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. Microbot began a limited market release of LIBERTY in late 2025 and plans a full market release at the Society of Interventional Radiology conference in April 2026.
Microbot Medical Inc. filed a report describing a press release about its LIBERTY® Endovascular Robotic System being highlighted at the International Symposium on Endovascular Therapy conference in Miami Beach, Florida.
The company notes that LIBERTY, described as the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, was prominently discussed in a town hall session on advances in endovascular robotics. Management states that LIBERTY is in a limited market release that began in late 2025 and that a full market release is planned at the Society of Interventional Radiology conference in April 2026.
Microbot Medical Inc. filed a report stating that it is attending the Society of Interventional Oncology annual meeting in Savannah, Georgia, held February 4–8, 2026. The timing coincides with the company’s limited market release of its LIBERTY Endovascular Robotic System.
During the meeting, Microbot plans to share practical insights and personal experiences from physicians who have used LIBERTY across different hospitals and procedure types. The company furnished, but did not file, a related press release as Exhibit 99.1 under Regulation FD.
Microbot Medical Inc. investors report an 8.2% beneficial stake in the company’s common stock. The filing is a Schedule 13G submitted jointly by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC. As of the close of business on January 23, 2026, they report beneficial ownership of 6,002,185 shares of common stock, all issuable upon exercise of a warrant held by Intracoastal. This stake is calculated as approximately 8.2% of the common stock, based on 67,158,044 shares outstanding as of November 14, 2025 plus the warrant shares. The reporting persons have shared, but not sole, voting and dispositive power over these shares and certify they do not hold the securities for the purpose of changing or influencing control of the issuer.